Waystar Evaluates Strategic Options, Considers Potential Sale
Healthcare software firm Waystar may pursue a sale, just two years after its IPO, amid declining market value.
Waystar, a healthcare software provider known for its administrative automation solutions, is reportedly exploring strategic options, including a potential sale. This development comes two years after the company's public listing on the New York Stock Exchange. According to seven insiders familiar with the situation, investment bank Evercore has been engaged to guide the process, which remains at a preliminary stage.
Based in Lehi, Utah, and Louisville, Kentucky, Waystar's technology assists hospitals and healthcare providers in managing payments. The company has positioned itself as a tech-driven entity, focusing on software solutions rather than labor-intensive services. This strategy was intended to attract higher valuations typical of technology firms.
Market Challenges and Investor Concerns
Despite initial investor enthusiasm, which saw Waystar's share price climb from $20 to a high of $45 in 2025, the stock has since suffered. A 24% decline this year has reduced the company's market value to approximately $4.8 billion. This downturn is part of a broader selloff in the software sector, influenced by concerns over the impact of advancements in artificial intelligence, as noted by Morgan Stanley analysts in a July report.
The potential sale could test investor interest in software businesses amidst these market conditions. However, sources caution that plans are still fluid, and a sale may not ultimately occur. Both Waystar and Evercore have declined to comment on the matter.
Ownership and Financial Backing
Waystar was established in 2017 following a merger between Zirmed and Navicure, two healthcare revenue management companies. It went public in 2024, backed by major investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT currently holds a 13% stake, making it the largest shareholder, followed by CPPIB with 10% and BlackRock Institutional Trust Company with 8%, as per LSEG data.
Neither EQT nor CPPIB provided immediate responses to requests for comments, while BlackRock declined to comment on the ongoing situation.
Strategic Positioning
Waystar's business model focuses on automating healthcare administrative tasks, aiming to distinguish itself from traditional service-based healthcare companies. This approach was designed to capitalize on the premium valuations associated with tech companies. However, the firm's current market challenges highlight the volatility and competitive pressures within the software industry.
As Waystar navigates these challenges and evaluates its future, the company's decisions will be closely watched by industry analysts and investors alike. The outcome of this process could have significant implications for its stakeholders and the broader healthcare software sector.